NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. – Trademark Portfolio

Entity Type: 03

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include FAMVIR and DENAVIR. The owner is based in HAMILTON HM LX.

12 TROTT ROAD

HURST HOLME

HAMILTON HM LX , BM

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (12 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. have?

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. has 12 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 5 cancelled.

What trademark classes does NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. file in?

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.'s most well-known trademarks?

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.'s registered trademark portfolio includes well-known marks such as FAMVIR and DENAVIR. These are among 3 currently registered trademarks in the portfolio.

What is NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.'s trademark registration success rate?

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. has a 25% trademark registration rate, with 3 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.